美股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

亚盛医药

32.71

-1.5900-4.64%

盘后：32.710.00000.00%16:10 EST

成交量：1,851.00

成交额：6.13万

市值：30.53亿

市盈率：-16.52

高：32.71

开：32.71

低：32.71

收：34.30

52周最高：48.45

52周最低：16.50

股本：9,333.04万

流通股本：7,158.28万

量比：0.28

换手率：0.00%

股息：- -

股息率：- -

每股收益(TTM):-1.9795

每股收益(LYR):-0.7356

净资产收益率：-159.65%

总资产收益率：-22.77%

市净率：32.61

市盈率(LYR):-44.47

数据加载中...

总览公司新闻资讯公告

亚盛医药：Piper Sandler发布覆盖评级，给予超配评级；目标价48美元

【2025 ASH】亚盛医药耐立克®多项研究入选，POLARIS-1研究数据首次发布

亚盛医药-B(06855)耐立克®、利生妥®、APG-5918的多项临床进展将在2025年美国血液学会年会(ASH)展示，其中一项获口头报告

全球重磅会议ESMO进入倒计时，高弹性港股通创新药ETF（520880）冲高2%！三生制药、亚盛医药-B强势领衔

美联储10月降息概率高达92%，港股医药高位回落

每日经济新闻

每日卖空追踪 | 亚盛医药-B 09月10日卖空量成交12.35万股，卖空比例为5.15%

亚盛医药上涨2.12%，报41.357美元/股，总市值38.53亿美元

亚盛医药-B09月01日主力净流入1697.0万元散户资金抛售

异动解读 | 亚盛医药盘中大跌5.25%，生物医药板块整体承压

港股生物医药股震荡回调，欧康维视生物跌超15%，百奥赛图、中国抗体跌超8.5%，亚盛医药跌超6%。

中金：维持亚盛医药-B(06855)跑赢行业评级升目标价至105港元

亚盛医药-B：耐立克放量迅速利生妥再加码差异化布局

每日卖空追踪 | 亚盛医药-B 08月22日卖空量成交17万股，卖空比例为5.56%

亚盛医药-B08月22日获主力加仓1782.2万元

亚盛医药耐立克销售收入同比激增93%，医保覆盖成关键驱动力

亚盛医药2025年中报：耐立克销售大增93%，利生妥®获批撬动双引擎

亚盛医药-B(06855)中报观：年内股价翻倍上市新高不断刷新，双“十亿美元分子”打开估值天花板

亚盛医药-B(06855)中期同比盈转亏至5.91亿元人民币

亚盛医药在港交所公告截至2025年6月30日止六个月收益为人民币2.34亿元同比减少71.6%主要是由于截至2024年6

亚盛医药-B(06855)发布中期业绩收益2.34亿元耐立克® (奥雷巴替尼)在中国的产品销售同比大幅增长93%

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/AAPG/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AAPG","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AAPG\",,,,,undefined,":{"symbol":"AAPG","market":"US","secType":"STK","nameCN":"亚盛医药","latestPrice":32.71,"timestamp":1763413200000,"preClose":34.3,"halted":0,"volume":1851,"hourTrading":{"tag":"盘后","latestPrice":32.71,"preClose":32.71,"latestTime":"16:10 EST","volume":2,"amount":65.42,"timestamp":1763413804114},"delay":0,"floatShares":71582800,"shares":93330405,"eps":-1.979486,"marketStatus":"未开盘","change":-1.59,"latestTime":"11-17 16:00:00 EST","open":32.71,"high":32.71,"low":32.71,"amount":61259.7596,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.979486,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1763456400000},"marketStatusCode":0,"adr":0,"adrRate":4,"listingDate":1737694800000,"exchange":"NASDAQ","adjPreClose":34.3,"preHourTrading":{"tag":"盘前","latestPrice":34,"preClose":34.3,"latestTime":"08:27 EST","volume":200,"amount":6800,"timestamp":1763386049775},"postHourTrading":{"tag":"盘后","latestPrice":32.71,"preClose":32.71,"latestTime":"16:10 EST","volume":2,"amount":65.42,"timestamp":1763413804114},"volumeRatio":0.276475},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AAPG\",,,,,undefined,":{"symbol":"AAPG","floatShares":71582800,"roa":"-22.77%","roe":"-159.65%","lyrEps":-0.735552,"volumeRatio":0.276475,"shares":93330405,"dividePrice":0,"high":32.71,"amplitude":0,"preClose":34.3,"low":32.71,"week52Low":16.5,"pbRate":"32.61","psRate":"55.60","week52High":48.45,"institutionHeld":0,"latestPrice":32.71,"eps":-1.979486,"divideRate":0,"volume":1851,"delay":0,"ttmEps":-1.979486,"open":32.71,"prevYearClose":17.25,"prevWeekClose":34.3,"prevMonthClose":33.42,"prevQuarterClose":39.04,"fiveDayClose":32.4,"twentyDayClose":35.31,"sixtyDayClose":47.9},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AAPG\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-20","symbol":"AAPG","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"盘后","type":"earning","dateTimestamp":1755662400000,"reportTimeType":"post","actualEps":null},{"date":"2025-03-27","symbol":"AAPG","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2024/12","expectedEps":null,"defaultRemindTime":1743062400000,"name":null,"time":"盘前","dateTimestamp":1743048000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AAPG\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AAPG\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.75,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.75,"analysts":4,"updateTime":1762578000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AAPG\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AAPG","date":"2025-11-14","current":-17.24185,"percent":0.930693,"low":-76.454813,"twenty":-55.920234,"median":-33.485756,"eighty":-22.342071,"high":-18.112503,"avg":-37.21958,"sd":15.491716,"marketCap":3199584585.23},"quantilePoints":[{"date":"2025-01-31","current":-29.751262,"twenty":-29.75286,"median":-29.751983,"eighty":-29.751262,"marketCap":1478269659.08},{"date":"2025-02-07","current":-32.664532,"twenty":-32.365221,"median":-31.242401,"eighty":-29.752127,"marketCap":1614694688.16},{"date":"2025-02-14","current":-31.1828,"twenty":-32.258438,"median":-31.212601,"eighty":-29.752938,"marketCap":1540476496.81},{"date":"2025-02-21","current":-36.382297,"twenty":-32.721933,"median":-31.802125,"eighty":-29.819279,"marketCap":1806628873.73},{"date":"2025-02-28","current":-33.43308,"twenty":-34.468465,"median":-32.375664,"eighty":-30.230932,"marketCap":1654638501.56},{"date":"2025-03-07","current":-34.452224,"twenty":-34.328072,"median":-32.712367,"eighty":-30.892818,"marketCap":1712841480.27},{"date":"2025-03-14","current":-33.065652,"twenty":-34.096417,"median":-32.760201,"eighty":-31.20664,"marketCap":1644428002.08},{"date":"2025-03-21","current":-32.72391,"twenty":-34.124503,"median":-32.947597,"eighty":-31.448698,"marketCap":1626713850.02},{"date":"2025-03-28","current":-33.955809,"twenty":-34.124503,"median":-33.010704,"eighty":-31.793328,"marketCap":1894714451.86},{"date":"2025-04-04","current":-35.921968,"twenty":-34.855052,"median":-33.21342,"eighty":-31.979778,"marketCap":2000185586.04},{"date":"2025-04-11","current":-29.511221,"twenty":-34.370118,"median":-33.010704,"eighty":-30.892818,"marketCap":1635879540.94},{"date":"2025-04-17","current":-29.520055,"twenty":-34.225935,"median":-32.760201,"eighty":-30.07059,"marketCap":1639709582.7},{"date":"2025-04-25","current":-41.553435,"twenty":-35.045268,"median":-32.920123,"eighty":-30.119556,"marketCap":2311372741.24},{"date":"2025-05-02","current":-38.492689,"twenty":-35.554336,"median":-33.187028,"eighty":-30.682879,"marketCap":2146245101.28},{"date":"2025-05-09","current":-37.35919,"twenty":-36.170996,"median":-33.361942,"eighty":-30.776099,"marketCap":2093177176.92},{"date":"2025-05-16","current":-35.007117,"twenty":-35.955639,"median":-33.43308,"eighty":-31.102567,"marketCap":1969122395.28},{"date":"2025-05-23","current":-39.338512,"twenty":-36.352488,"median":-33.608398,"eighty":-31.19472,"marketCap":2213435510.22},{"date":"2025-05-30","current":-38.856398,"twenty":-37.35919,"median":-33.992043,"eighty":-31.242401,"marketCap":2192363417.29},{"date":"2025-06-06","current":-42.814884,"twenty":-37.865895,"median":-34.141844,"eighty":-31.758144,"marketCap":2419987007.19},{"date":"2025-06-13","current":-48.171029,"twenty":-38.492689,"median":-34.477812,"eighty":-31.846105,"marketCap":2722575737.57},{"date":"2025-06-20","current":-55.929302,"twenty":-38.862859,"median":-34.635358,"eighty":-32.113451,"marketCap":3154688383.5},{"date":"2025-06-27","current":-59.787237,"twenty":-39.399619,"median":-35.123604,"eighty":-32.336589,"marketCap":3381751544.24},{"date":"2025-07-03","current":-64.068526,"twenty":-41.436089,"median":-35.258863,"eighty":-32.429915,"marketCap":3624015684.35},{"date":"2025-07-11","current":-59.084566,"twenty":-43.897892,"median":-35.501693,"eighty":-32.48435,"marketCap":3338745741.38},{"date":"2025-07-18","current":-61.880278,"twenty":-48.308604,"median":-35.791073,"eighty":-32.545465,"marketCap":3494679880.36},{"date":"2025-07-25","current":-58.315576,"twenty":-54.849764,"median":-35.921968,"eighty":-32.616809,"marketCap":3304687864.64},{"date":"2025-08-01","current":-60.559654,"twenty":-57.422661,"median":-36.233253,"eighty":-32.655768,"marketCap":3410643633.03},{"date":"2025-08-08","current":-69.260076,"twenty":-59.023969,"median":-36.597865,"eighty":-32.679287,"marketCap":3910472388.03},{"date":"2025-08-15","current":-72.346957,"twenty":-59.602544,"median":-37.391167,"eighty":-32.709995,"marketCap":4086922647.44},{"date":"2025-08-22","current":-26.724459,"twenty":-60.097702,"median":-37.493155,"eighty":-32.679287,"marketCap":4314209810.62},{"date":"2025-08-29","current":-24.396919,"twenty":-59.865528,"median":-36.699167,"eighty":-32.48435,"marketCap":3966417985.85},{"date":"2025-09-05","current":-22.946281,"twenty":-59.664109,"median":-36.382297,"eighty":-31.979778,"marketCap":3724203040.4},{"date":"2025-09-12","current":-22.941741,"twenty":-59.475774,"median":-35.943012,"eighty":-31.122625,"marketCap":3735810338.07},{"date":"2025-09-19","current":-21.785524,"twenty":-59.316014,"median":-35.857966,"eighty":-29.943039,"marketCap":3550375801.58},{"date":"2025-09-26","current":-21.102028,"twenty":-59.062646,"median":-35.66937,"eighty":-29.751262,"marketCap":3428719452.06},{"date":"2025-10-03","current":-22.266298,"twenty":-59.025902,"median":-35.30284,"eighty":-28.699054,"marketCap":3625414266.5},{"date":"2025-10-10","current":-21.050291,"twenty":-58.738293,"median":-35.189473,"eighty":-26.732175,"marketCap":3423480133.18},{"date":"2025-10-17","current":-19.80269,"twenty":-58.191808,"median":-34.731922,"eighty":-24.468638,"marketCap":3221889328.22},{"date":"2025-10-24","current":-19.801335,"twenty":-57.904825,"median":-34.477812,"eighty":-23.569995,"marketCap":3222890223.42},{"date":"2025-10-31","current":-19.321494,"twenty":-57.532716,"median":-34.141844,"eighty":-22.943557,"marketCap":3150231208.59},{"date":"2025-11-07","current":-18.112503,"twenty":-56.69325,"median":-33.992043,"eighty":-22.558349,"marketCap":2949090425.48},{"date":"2025-11-14","current":-19.583345,"twenty":-55.920234,"median":-33.485756,"eighty":-22.342071,"marketCap":3199584585.23}],"updateTime":1763411590200},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AAPG\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1163861320","title":"亚盛医药：Piper Sandler发布覆盖评级，给予超配评级；目标价48美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1163861320","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163861320?lang=zh_cn&edition=fundamental","pubTime":"2025-11-05 17:03","pubTimestamp":1762333390,"startTime":"0","endTime":"0","summary":"亚盛医药：Piper Sandler发布覆盖评级，给予超配评级；目标价48美元","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AAPG","BK1574","06855","BK4139","BK1161"],"gpt_icon":0},{"id":"2580279202","title":"【2025 ASH】亚盛医药耐立克®多项研究入选，POLARIS-1研究数据首次发布","url":"https://stock-news.laohu8.com/highlight/detail?id=2580279202","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580279202?lang=zh_cn&edition=fundamental","pubTime":"2025-11-04 09:21","pubTimestamp":1762219260,"startTime":"0","endTime":"0","summary":"公司将在此次ASH年会上，首次发布耐立克联合低强度化疗治疗初治费城染色体阳性（Ph+）急性淋巴细胞白血病患者的全球III期研究最新数据。一年一度的ASH年会是全球血液学领域规模最大的国际学术盛会之一，全面涵盖了血液疾病的病因研究和治疗研究。此外，今年公司3个重点品种有多项进展入选ASH年会展示及报告，充分显现了公司的全球创新和开发实力。未来，亚盛医药将进一步加速推进临床开发，早日为患者带来更多治疗选择。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4814666_ZH14666_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["AAPG","BK4109","BK1574","06855","LU2463526074.USD","BK4139","BK1161","ASH"],"gpt_icon":0},{"id":"2580220496","title":"亚盛医药-B(06855)耐立克®、利生妥®、APG-5918的多项临床进展将在2025年美国血液学会年会(ASH)展示，其中一项获口头报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2580220496","media":"智通财经","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580220496?lang=zh_cn&edition=fundamental","pubTime":"2025-11-04 08:21","pubTimestamp":1762215703,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B 发布公告，公司3个品种有多项临床和临床前进展入选第67届美国血液学会年会展示及报告，其中一项获口头报告。此外，公司原创1类新药利沙托克拉共 有 2项临床进展获选第67届ASH年会，其中一项获口头报告。这是该品种的临床进展连续第4年入选 ASH年会。第67届ASH年会将于当地时间2025年12月6 日至12月9日间在美国佛罗里达州奥兰多市以线下结合线上的形式举行。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1364794.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2125909759.SGD","BK1161","BK4139","LU2463526074.USD","BK4109","LU1923622291.USD","APG","BK4129","LU2125909916.SGD","ASH","BK1574","AAPG","06855"],"gpt_icon":0},{"id":"2575720858","title":"全球重磅会议ESMO进入倒计时，高弹性港股通创新药ETF（520880）冲高2%！三生制药、亚盛医药-B强势领衔","url":"https://stock-news.laohu8.com/highlight/detail?id=2575720858","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575720858?lang=zh_cn&edition=fundamental","pubTime":"2025-10-15 14:30","pubTimestamp":1760509800,"startTime":"0","endTime":"0","summary":"10月15日午后，港股通创新药板块持续拉升，亚盛医药-B领涨近6%，科伦博泰生物-B、同源康医药-B、三生制药等多股反弹逾4%。　　港股通创新药ETF100%布局创新药研发类公司，午后震荡上扬，场内涨幅一度冲上2%，成交超3.4亿元。此前3日港股通创新药ETF已获超1.29亿元资金逢跌净申购。　　产业方面，日前诺诚健华达成1亿美金首付款、总价超过20亿美金BD交易。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2025-10-15/doc-inftxywn3617176.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["01530","BK1574","06855","520880","BK1161","BK1593","BK1583","AAPG","BK4139"],"gpt_icon":0},{"id":"2569099557","title":"美联储10月降息概率高达92%，港股医药高位回落","url":"https://stock-news.laohu8.com/highlight/detail?id=2569099557","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569099557?lang=zh_cn&edition=fundamental","pubTime":"2025-09-24 10:11","pubTimestamp":1758679917,"startTime":"0","endTime":"0","summary":"美联储于9月18日如期宣布降息25bp，为港股市场提供了较为宽松的流动性环境。但当前距离10月29日议息尚有35天，美联储相关官员的发言在短期内引起较大扰动。据CME FedWatch Tool数据，美联储10月降息25bp的概率为91.9%；12月降息25bp的概率为21.7%，降息50bp的概率为77%。从二级市场来看，聚焦港股市场创新药+CXO的恒生医药ETF连续调整，自阶段高点回落近6%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025092410141595415b18&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"ea3b3b54e2aa42d2aadd6617f904fcb8","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025092410141595415b18&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09688","09606","SPY","SH","BK4534","SDS","BK4139","AAPG","BK4550","BK4581","BK4588",".SPX","SSO","BK4585","UPRO","BK4559","BK4504","ESmain","IVV","SPXU","OEF","OEX","MESmain"],"gpt_icon":0},{"id":"2566698828","title":"每日卖空追踪 | 亚盛医药-B 09月10日卖空量成交12.35万股，卖空比例为5.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2566698828","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566698828?lang=zh_cn&edition=fundamental","pubTime":"2025-09-10 16:30","pubTimestamp":1757493041,"startTime":"0","endTime":"0","summary":"亚盛医药-B北京时间09月10日，跌1.68%，卖空量成交12.35万股，较上一交易日减少57.81%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025091016350697851d0e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025091016350697851d0e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AAPG"],"gpt_icon":0},{"id":"2565870726","title":"亚盛医药上涨2.12%，报41.357美元/股，总市值38.53亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2565870726","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565870726?lang=zh_cn&edition=fundamental","pubTime":"2025-09-08 22:16","pubTimestamp":1757340962,"startTime":"0","endTime":"0","summary":"据交易所数据显示，9月8日，亚盛医药盘中上涨2.12%，截至22:16，报41.357美元/股，成交48.07万美元，总市值38.53亿美元。财务数据显示，截至2025年06月30日，亚盛医药收入总额2.34亿人民币，同比减少71.63%；归母净利润-5.91亿人民币，同比减少462.43%。目前公司正在中国、美国、澳大利亚及欧洲开展40多项临床试验。截至目前,公司共有4个在研新药获得16项FDA和1项欧盟孤儿药资格认定,2项FDA快速通道资格以及2项FDA儿童罕见病资格认证。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/09/08221653004732.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK4139","AAPG"],"gpt_icon":0},{"id":"2564781953","title":"亚盛医药-B09月01日主力净流入1697.0万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2564781953","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564781953?lang=zh_cn&edition=fundamental","pubTime":"2025-09-01 16:15","pubTimestamp":1756714535,"startTime":"0","endTime":"0","summary":"09月01日, 亚盛医药-B股价涨0.12%，报收83.25元，成交金额2.4亿元，换手率0.78%，振幅2.77%，量比0.59。亚盛医药-B今日主力资金净流入1697.0万元，上一交易日主力净流出815.6万元。该股近5个交易日下跌3.42%，主力资金累计净流出1557.3万元，其中2个交易日为股价上涨时净流出；近20日主力资金累计净流入5220.1万元，其中净流入天数为8日。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250901170942a7090fba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250901170942a7090fba&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AAPG","BK4139"],"gpt_icon":0},{"id":"1136407164","title":"异动解读 | 亚盛医药盘中大跌5.25%，生物医药板块整体承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1136407164","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136407164?lang=zh_cn&edition=fundamental","pubTime":"2025-08-25 21:32","pubTimestamp":1756128779,"startTime":"0","endTime":"0","summary":"8月25日周一盘中，亚盛医药股价出现大幅下跌，跌幅达5.25%，引发市场关注。此次下跌主要受到生物医药板块整体走弱的影响。其中，欧康维视生物跌幅超过15%，百奥赛图和中国抗体跌幅均超过8.5%，亚盛医药跌幅超过6%。这一行业性下跌趋势可能是导致亚盛医药股价下跌的主要原因。值得注意的是，尽管股价下跌，但亚盛医药近期获得了积极的分析师评价。中金公司维持亚盛医药\"跑赢行业\"评级，并将目标价上调19.3%至105港元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AAPG"],"gpt_icon":0},{"id":"2562291249","title":"港股生物医药股震荡回调，欧康维视生物跌超15%，百奥赛图、中国抗体跌超8.5%，亚盛医药跌超6%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2562291249","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562291249?lang=zh_cn&edition=fundamental","pubTime":"2025-08-25 10:51","pubTimestamp":1756090312,"startTime":"0","endTime":"0","summary":"港股生物医药股震荡回调，欧康维视生物跌超15%，百奥赛图、中国抗体跌超8.5%，亚盛医药跌超6%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/08/25105152660744.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["HSTECH","BK4614","BK1161","161726","AAPG","03681","HSCEI","BK4139","BK1574","YANG","07226","399441"],"gpt_icon":0},{"id":"2562291614","title":"中金：维持亚盛医药-B(06855)跑赢行业评级 升目标价至105港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2562291614","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562291614?lang=zh_cn&edition=fundamental","pubTime":"2025-08-25 10:39","pubTimestamp":1756089589,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，维持亚盛医药-B2025年/2026年归母净利润预测不变，维持跑赢行业评级，考虑到GLORA-4进展，新适应症空间可见度提升，根据DCF模型，上调目标价19.3%至105港币，离当前股价有15.8%的上行空间。公司1H25收入2.34亿元，主要由于去年同期产生授权收入，1H25业绩符合该行预期。该行认为MDS患者人群广泛，一线治疗存在较大未满足需求，公司利生妥这一布局有望加码其差异化优势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1334247.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06855","AAPG"],"gpt_icon":0},{"id":"2561250107","title":"亚盛医药-B：耐立克放量迅速 利生妥再加码差异化布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2561250107","media":"中金公司","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561250107?lang=zh_cn&edition=fundamental","pubTime":"2025-08-24 00:00","pubTimestamp":1755964800,"startTime":"0","endTime":"0","summary":"发展趋势耐立克新适应进入医保带来上半年商业化收入高速增长，下半年利沙妥克拉获批上市有望贡献新增长点。根据公司公告，截至公告日，利生妥是国际唯一正推进中高危MDS 注册III 期临床的Bcl-2 抑制剂，有望打破该领域长期空白。此前2025ASCO 上发表的数据表明，利生妥联合阿扎胞苷治疗初治MDS 的ORR 达到75%，且安全性良好。我们认为MDS 患者人群广泛，一线治疗存在较大未满足需求，公司利生妥这一布局有望加码其差异化优势。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250824143619a6f81ba9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250824143619a6f81ba9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AAPG"],"gpt_icon":0},{"id":"2561147611","title":"每日卖空追踪 | 亚盛医药-B 08月22日卖空量成交17万股，卖空比例为5.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2561147611","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561147611?lang=zh_cn&edition=fundamental","pubTime":"2025-08-22 16:30","pubTimestamp":1755851437,"startTime":"0","endTime":"0","summary":"亚盛医药-B北京时间08月22日，涨0.5%，卖空量成交17万股%，较上一交易日减少39.2%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250822174123a4983e1c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250822174123a4983e1c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AAPG"],"gpt_icon":0},{"id":"2561476199","title":"亚盛医药-B08月22日获主力加仓1782.2万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2561476199","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561476199?lang=zh_cn&edition=fundamental","pubTime":"2025-08-22 16:15","pubTimestamp":1755850533,"startTime":"0","endTime":"0","summary":"08月22日, 亚盛医药-B股价涨0.50%，报收90.65元，成交金额2.8亿元，换手率0.82%，振幅3.82%，量比0.68。亚盛医药-B今日主力资金净流入1782.2万元，上一交易日主力净流入1179.5万元。该股近5个交易日上涨5.05%，主力资金累计净流出1001.0万元；近20日主力资金累计净流入6971.9万元，其中净流入天数为9日。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250822170525a6f52b47&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250822170525a6f52b47&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AAPG","BK4139"],"gpt_icon":0},{"id":"2561761424","title":"亚盛医药耐立克销售收入同比激增93%，医保覆盖成关键驱动力","url":"https://stock-news.laohu8.com/highlight/detail?id=2561761424","media":"DoNews","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561761424?lang=zh_cn&edition=fundamental","pubTime":"2025-08-22 12:16","pubTimestamp":1755836163,"startTime":"0","endTime":"0","summary":"亚盛医药近日公布2025年上半年业绩，其核心产品耐立克销售收入同比增长93%，达到人民币2.17亿元。业绩显著增长主要得益于该药物被纳入国家医保目录后覆盖范围的持续扩大，市场可及性进一步提升。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025082212192194f3cd4c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025082212192194f3cd4c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AAPG"],"gpt_icon":0},{"id":"2561369374","title":"亚盛医药2025年中报：耐立克销售大增93%，利生妥®获批撬动双引擎","url":"https://stock-news.laohu8.com/highlight/detail?id=2561369374","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561369374?lang=zh_cn&edition=fundamental","pubTime":"2025-08-21 09:05","pubTimestamp":1755738302,"startTime":"0","endTime":"0","summary":"头部创新药企业亚盛医药今日公布2025年上半年业绩。报告期内，公司收入2.34亿人民币，其中耐立克销售收入达2.17亿人民币，同比增长93%，主要源于耐立克已获批适应症全部纳入医保后的放量增长。利生妥的上市意味着亚盛医药正式迈入双引擎驱动增长时期，商业化按下加速键。今年1月24日，亚盛医药在美股纳斯达克上市，成为首家先港股、后美股双重主要上市的生物医药企业。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/08/21090552580386.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK4139","AAPG"],"gpt_icon":0},{"id":"2561436356","title":"亚盛医药-B(06855)中报观：年内股价翻倍上市新高不断刷新，双“十亿美元分子”打开估值天花板","url":"https://stock-news.laohu8.com/highlight/detail?id=2561436356","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561436356?lang=zh_cn&edition=fundamental","pubTime":"2025-08-21 09:02","pubTimestamp":1755738154,"startTime":"0","endTime":"0","summary":"近日，亚盛医药-B盘中股价触及95.35港元，刷新公司上市以来股价新高。至此，公司年初至今股价已翻倍，涨幅高达100.88%。从亚盛医药最新披露的2025年中报数据来看，报告期内，亚盛医药实现收入人民币2.34亿元。7月10日，亚盛医药1类新药利沙托克拉片(利生妥)正式获批上市，成为国内获批的首款国产BCL-2抑制剂。今年7月8日，亚盛医药宣布了两位资深高管的加入。显然，在第二款“十亿美元分子”顺利上市后，亚盛医药已迈向新的历史发展阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1332543.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","AAPG","BK1574","06855","BK1161"],"gpt_icon":0},{"id":"2561105435","title":"亚盛医药-B(06855)中期同比盈转亏至5.91亿元人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=2561105435","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561105435?lang=zh_cn&edition=fundamental","pubTime":"2025-08-21 08:59","pubTimestamp":1755737999,"startTime":"0","endTime":"0","summary":"金吾财讯 | 亚盛医药-B(06855)公布，截至2025年6月30日止六个月未经审核中期业绩。公司普通权益持有人应占亏损5.91亿元(人民币，下同)，同比盈转亏。每股基本亏损1.73元，去年同期为盈利0.56元。期内，集团收益2.34亿元，同比减少71.63%。其中，耐立克(奥雷巴替尼)在中国的产品销售较截至2024年6月30日止6个月的人民币1.13亿元，增加人民币1.05亿元或93%至2025年上半年的人民币2.17亿元。期内，研发开支5.29亿元，同比增长19%，主要是由于与集团正在进行的全球临床试验相关的外部研发开支增加。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250110/MzFkZTQ1MjU5YjFkNTI3NmM3M2EwODA1ODY2NzgzMDk4MzEw.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MzFkZTQ1MjU5YjFkNTI3NmM3M2EwODA1ODY2NzgzMDk4MzEw.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1964482","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MUCmain","CNHmain","CYB","UCmain","AAPG","BK1161","BK1574","06855","BK4139","MCNHmain"],"gpt_icon":0},{"id":"2561069480","title":"亚盛医药在港交所公告截至2025年6月30日止六个月收益为人民币2.34亿元同比减少71.6%主要是由于截至2024年6","url":"https://stock-news.laohu8.com/highlight/detail?id=2561069480","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561069480?lang=zh_cn&edition=fundamental","pubTime":"2025-08-21 07:31","pubTimestamp":1755732670,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["CNHmain","BK4139","MUCmain","HEXmain","AAPG","MCNHmain","UCmain","CYB"],"gpt_icon":0},{"id":"2561248075","title":"亚盛医药-B(06855)发布中期业绩 收益2.34亿元 耐立克® (奥雷巴替尼)在中国的产品销售同比大幅增长93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2561248075","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561248075?lang=zh_cn&edition=fundamental","pubTime":"2025-08-21 07:21","pubTimestamp":1755732077,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B 发布截至2025年6月30日止6个月业绩，该集团期内取得收益为人民币2.34亿元。耐立克 在中国的产品销售较截至2024年6月30日止6个月的人民币1.13亿元，增加人民币1.05亿元或93%至2025年上半年的人民币2.17亿元。截至2025年6月30日止6个月研发开支增加人民币8450万元或19.0%至人民币5.29亿元，主要是由于与集团正在进行的全球临床试验相关的外部研发开支增加。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1332510.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"亚盛医药-B(06855)发布中期业绩 收益2.34亿元 耐立克® (奥雷巴替尼)在中国的产品销售同比大幅增长93%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06855","BK4139","AAPG","BK1161","BK1574"],"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":1,"totalSize":123,"code":"91000000","status":"200"}]}}